EGL-001, a new immunocytokine with unique mechanism, demonstrates potent antitumor efficacy
May 3, 2024
Researchers from Egle Therapeutics SAS presented the discovery of a novel immunocytokine, EGL-001, designed to selectively target tumor-infiltrating regulatory T cells (Tregs).
